{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:42:49Z","timestamp":1793403769735,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001646","name":"Robert Bosch Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Soft tissue sarcomas (STS) are a heterogeneous group of malignancies predominantly affecting children and young adults. Despite improvements in multimodal therapies, 5-year survival rates are only 50% and new treatment options in STS are urgently needed. To develop a rational combination therapy for the treatment of STS we focused on ABT-199 (Venetoclax), a BCL-2 specific BH3-mimetic, in combination with the proteasome inhibitor bortezomib (BZB). Simultaneous inhibition of BCL-2 and the proteasome resulted in strongly synergistic apoptosis induction. Mechanistically, ABT-199 mainly affected the multidomain effector BAX by liberating it from BCL-2 inhibition. The combination with BZB additionally resulted in the accumulation of BOK, a BAX\/BAK homologue, and of the BH3-only protein NOXA, which inhibits the anti-apoptotic protein MCL-1. Thus, the combination of ABT-199 and BZB sensitizes STS cells to apoptosis by simultaneously releasing several defined apoptotic restraints. This synergistic mechanism of action was verified by CRISPR\/Cas9 knock-out, showing that both BAX and NOXA are crucial for ABT-199\/BZB-induced apoptosis. Noteworthy, efficient induction of apoptosis by ABT-199\/BZB was not affected by the p53 status and invariably detected in cell lines and patient-derived tumor cells of several sarcoma types, including rhabdomyo-, leiomyo-, lipo-, chondro-, osteo-, or synovial sarcomas. Hence, we propose the combination of ABT-199 and BZB as a promising strategy for the treatment of STS, which should warrant further clinical investigation.<\/jats:p>","DOI":"10.1038\/s41419-020-02910-2","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:02:26Z","timestamp":1598313746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA"],"prefix":"10.1038","volume":"11","author":[{"given":"Alina","family":"Muenchow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Hinterleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Malenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Bugl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wirths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1443-2720","authenticated-orcid":false,"given":"Klaus","family":"Schulze-Osthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Aulitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-8456","authenticated-orcid":false,"given":"Frank","family":"Essmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"2910_CR1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2147\/CMAR.S159641","volume":"10","author":"NT Hoang","year":"2018","unstructured":"Hoang, N. T., Acevedo, L. A., Mann, M. J. & Tolani, B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag. Res. 10, 1089\u20131114 (2018).","journal-title":"Cancer Manag. Res."},{"key":"2910_CR2","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.18632\/oncotarget.3498","volume":"6","author":"S Movva","year":"2015","unstructured":"Movva, S. et al. Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget 6, 12234\u201312247 (2015).","journal-title":"Oncotarget"},{"key":"2910_CR3","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1200\/JCO.2003.02.026","volume":"21","author":"J Weitz","year":"2003","unstructured":"Weitz, J., Antonescu, C. R. & Brennan, M. F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J. Clin. Oncol. 21, 2719\u20132725 (2003).","journal-title":"J. Clin. Oncol."},{"key":"2910_CR4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1758834017712963","volume":"9","author":"GK In","year":"2017","unstructured":"In, G. K., Hu, J. S. & Tseng, W. W. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther. Adv. Med. Oncol. 9, 533\u2013550 (2017).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2910_CR5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","volume":"18","author":"WD Tap","year":"2017","unstructured":"Tap, W. D. et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 18, 1089\u20131103 (2017).","journal-title":"Lancet Oncol."},{"key":"2910_CR6","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.molonc.2014.05.016","volume":"8","author":"SN Dumont","year":"2014","unstructured":"Dumont, S. N. et al. Targeted polytherapy in small cell sarcoma and its association with doxorubicin. Mol. Oncol. 8, 1458\u20131468 (2014).","journal-title":"Mol. Oncol."},{"key":"2910_CR7","doi-asserted-by":"crossref","first-page":"10075","DOI":"10.1200\/jco.2011.29.15_suppl.10075","volume":"29","author":"S Attia","year":"2011","unstructured":"Attia, S. et al. A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas. J. Clin. Oncol. 29, 10075\u201310075 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2910_CR8","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1158\/0008-5472.CAN-16-1040","volume":"76","author":"N Shukla","year":"2016","unstructured":"Shukla, N. et al. Proteasome addiction defined in ewing sarcoma is effectively targeted by a novel class of 19S proteasome inhibitors. Cancer Res. 76, 4525\u20134534 (2016).","journal-title":"Cancer Res."},{"key":"2910_CR9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.20968","volume":"103","author":"RG Maki","year":"2005","unstructured":"Maki, R. G. et al. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103, 1431\u20131438 (2005).","journal-title":"Cancer"},{"key":"2910_CR10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrc3087","volume":"11","author":"BS Taylor","year":"2011","unstructured":"Taylor, B. S. et al. Advances in sarcoma genomics and new therapeutic targets. Nat. Rev. Cancer 11, 541\u2013557 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"2910_CR11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cpt.553","volume":"101","author":"AW Roberts","year":"2017","unstructured":"Roberts, A. W. & Huang, D. Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. Clin. Pharmacol. Ther. 101, 89\u201398 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2910_CR12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd3137","volume":"9","author":"S Fulda","year":"2010","unstructured":"Fulda, S., Galluzzi, L. & Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 9, 447\u2013464 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2910_CR13","doi-asserted-by":"crossref","first-page":"12401","DOI":"10.1073\/pnas.94.23.12401","volume":"94","author":"SY Hsu","year":"1997","unstructured":"Hsu, S. Y., Kaipia, A., McGee, E., Lomeli, M. & Hsueh, A. J. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc. Natl Acad. Sci. USA 94, 12401\u201312406 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2910_CR14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30603-6","volume":"8","author":"D Stehle","year":"2018","unstructured":"Stehle, D. et al. Contribution of BH3-domain and Transmembrane-domain to the activity and interaction of the pore-forming Bcl-2 proteins Bok, Bak, and Bax. Sci. Rep. 8, 12434 (2018).","journal-title":"Sci. Rep."},{"key":"2910_CR15","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","volume":"19","author":"SN Willis","year":"2005","unstructured":"Willis, S. N. et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19, 1294\u20131305 (2005).","journal-title":"Genes Dev."},{"key":"2910_CR16","doi-asserted-by":"crossref","first-page":"18081","DOI":"10.1073\/pnas.0808691105","volume":"105","author":"JI Fletcher","year":"2008","unstructured":"Fletcher, J. I. et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc. Natl Acad. Sci. USA 105, 18081\u201318087 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2910_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","volume":"25","author":"JM Adams","year":"2018","unstructured":"Adams, J. M. & Cory, S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 25, 27\u201336 (2018).","journal-title":"Cell Death Differ."},{"key":"2910_CR18","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar, S. et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 130, 2401\u20132409 (2017).","journal-title":"Blood"},{"key":"2910_CR19","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1021\/jm501258m","volume":"58","author":"M Bruncko","year":"2015","unstructured":"Bruncko, M. et al. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. J. Med. Chem. 58, 2180\u20132194 (2015).","journal-title":"J. Med. Chem."},{"key":"2910_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.561","volume":"6","author":"JD Leverson","year":"2015","unstructured":"Leverson, J. D. et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 6, e1590 (2015).","journal-title":"Cell Death Dis."},{"key":"2910_CR21","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1242\/jcs.193946","volume":"129","author":"S Einsele-Scholz","year":"2016","unstructured":"Einsele-Scholz, S. et al. Bok is a genuine multi-BH-domain protein that triggers apoptosis in the absence of Bax and Bak. J. Cell Sci. 129, 3054 (2016).","journal-title":"J. Cell Sci."},{"key":"2910_CR22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2016.02.026","volume":"165","author":"F Llambi","year":"2016","unstructured":"Llambi, F. et al. BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation. Cell 165, 421\u2013433 (2016).","journal-title":"Cell"},{"key":"2910_CR23","doi-asserted-by":"crossref","first-page":"30944","DOI":"10.18632\/oncotarget.25801","volume":"9","author":"T Moldoveanu","year":"2018","unstructured":"Moldoveanu, T. & Zheng, J. H. Metastability, an emerging concept governing BOK-mediated apoptosis initiation. Oncotarget 9, 30944\u201330945 (2018).","journal-title":"Oncotarget"},{"key":"2910_CR24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","volume":"27","author":"DA Fennell","year":"2008","unstructured":"Fennell, D. A., Chacko, A. & Mutti, L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27, 1189\u20131197 (2008).","journal-title":"Oncogene"},{"key":"2910_CR25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jmb.2010.03.058","volume":"398","author":"S Dutta","year":"2010","unstructured":"Dutta, S. et al. Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL. J. Mol. Biol. 398, 747\u2013762 (2010).","journal-title":"J. Mol. Biol."},{"key":"2910_CR26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/cr.2010.149","volume":"21","author":"B Ku","year":"2011","unstructured":"Ku, B., Liang, C., Jung, J. U. & Oh, B. H. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 21, 627\u2013641 (2011).","journal-title":"Cell Res."},{"key":"2910_CR27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1039\/c1ib00023c","volume":"3","author":"S Zhang","year":"2011","unstructured":"Zhang, S. & Link, A. J. Bcl-2 family interactome analysis using bacterial surface display. Integr. Biol. 3, 823\u2013831 (2011).","journal-title":"Integr. Biol."},{"key":"2910_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 25, 65\u201380 (2018).","journal-title":"Cell Death Differ."},{"key":"2910_CR29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova, L., Pour, L., Sedlarikova, L., Hajek, R. & Sevcikova, S. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J. Cell. Mol. Med. 18, 947\u2013961 (2014).","journal-title":"J. Cell. Mol. Med."},{"key":"2910_CR30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351\u2013365 (2006).","journal-title":"Cancer Cell"},{"key":"2910_CR31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-319-91439-8_11","volume":"212","author":"A Scheffold","year":"2018","unstructured":"Scheffold, A., Jebaraj, B. M. C. & Stilgenbauer, S. Venetoclax: targeting BCL2 in hematological cancers. Recent Results Cancer Res. 212, 215\u2013242 (2018).","journal-title":"Recent Results Cancer Res."},{"key":"2910_CR32","first-page":"327","volume":"4","author":"SJ Korsmeyer","year":"1993","unstructured":"Korsmeyer, S. J., Shutter, J. R., Veis, D. J., Merry, D. E. & Oltvai, Z. N. Bcl-2\/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin. Cancer Biol. 4, 327\u2013332 (1993).","journal-title":"Semin. Cancer Biol."},{"key":"2910_CR33","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1074\/jbc.M610643200","volume":"282","author":"KW Adams","year":"2007","unstructured":"Adams, K. W. & Cooper, G. M. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J. Biol. Chem. 282, 6192\u20136200 (2007).","journal-title":"J. Biol. Chem."},{"key":"2910_CR34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0003-9861(03)00345-X","volume":"417","author":"D Iglesias-Serret","year":"2003","unstructured":"Iglesias-Serret, D., Pique, M., Gil, J., Pons, G. & Lopez, J. M. Transcriptional and translational control of Mcl-1 during apoptosis. Arch. Biochem. Biophys. 417, 141\u2013152 (2003).","journal-title":"Arch. Biochem. Biophys."},{"key":"2910_CR35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","volume":"139","author":"I Nicoletti","year":"1991","unstructured":"Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F. & Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139, 271\u2013279 (1991).","journal-title":"J. Immunol. Methods"},{"key":"2910_CR36","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/ml5001867","volume":"5","author":"ZF Tao","year":"2014","unstructured":"Tao, Z. F. et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med. Chem. Lett. 5, 1088\u20131093 (2014).","journal-title":"ACS Med. Chem. Lett."},{"key":"2910_CR37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cell.2011.02.034","volume":"145","author":"F Edlich","year":"2011","unstructured":"Edlich, F. et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 145, 104\u2013116 (2011).","journal-title":"Cell"},{"key":"2910_CR38","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1133289","volume":"315","author":"SN Willis","year":"2007","unstructured":"Willis, S. N. et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856\u2013859 (2007).","journal-title":"Science"},{"key":"2910_CR39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar, P. E., Lessene, G., Strasser, A. & Adams, J. M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49\u201363 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2910_CR40","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2008.11.010","volume":"135","author":"JF Lovell","year":"2008","unstructured":"Lovell, J. F. et al. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135, 1074\u20131084 (2008).","journal-title":"Cell"},{"key":"2910_CR41","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.celrep.2018.04.060","volume":"23","author":"JH Zheng","year":"2018","unstructured":"Zheng, J. H. et al. Intrinsic instability of BOK enables membrane permeabilization in apoptosis. Cell Rep. 23, 2083\u20132094. e6 (2018).","journal-title":"Cell Rep."},{"key":"2910_CR42","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2010.022368","volume":"95","author":"M Baou","year":"2010","unstructured":"Baou, M. et al. Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica 95, 1510\u20131518 (2010).","journal-title":"Haematologica"},{"key":"2910_CR43","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/cdd.2012.16","volume":"19","author":"A Craxton","year":"2012","unstructured":"Craxton, A. et al. NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1. Cell Death Differ. 19, 1424\u20131434 (2012).","journal-title":"Cell Death Differ."},{"key":"2910_CR44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids, M. S. et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J. Clin. Oncol. 35, 826\u2013833 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2910_CR45","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106\u20131117 (2016).","journal-title":"Cancer Discov."},{"key":"2910_CR46","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer, S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 17, 768\u2013778 (2016).","journal-title":"Lancet Oncol."},{"key":"2910_CR47","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey, H. E. et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 8, 1566\u20131581 (2018).","journal-title":"Cancer Discov."},{"key":"2910_CR48","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1074\/jbc.M109.038331","volume":"285","author":"J Hagenbuchner","year":"2010","unstructured":"Hagenbuchner, J. et al. The anti-apoptotic protein BCL2L1\/Bcl-xL is neutralized by pro-apoptotic PMAIP1\/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression. J. Biol. Chem. 285, 6904\u20136912 (2010).","journal-title":"J. Biol. Chem."},{"key":"2910_CR49","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","volume":"288","author":"E Oda","year":"2000","unstructured":"Oda, E. et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053\u20131058 (2000).","journal-title":"Science"},{"key":"2910_CR50","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/0008-5472.CAN-12-2876","volume":"73","author":"M Gutekunst","year":"2013","unstructured":"Gutekunst, M. et al. Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4. Cancer Res. 73, 1460\u20131469 (2013).","journal-title":"Cancer Res."},{"key":"2910_CR51","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/cdd.2013.10","volume":"20","author":"N Echeverry","year":"2013","unstructured":"Echeverry, N. et al. Intracellular localization of the BCL-2 family member BOK and functional implications. Cell Death Differ. 20, 785\u2013799 (2013).","journal-title":"Cell Death Differ."},{"key":"2910_CR52","doi-asserted-by":"crossref","first-page":"85984","DOI":"10.18632\/oncotarget.20841","volume":"8","author":"B Onyeagucha","year":"2017","unstructured":"Onyeagucha, B. et al. Novel post-transcriptional and post-translational regulation of pro-apoptotic protein BOK and anti-apoptotic protein Mcl-1 determine the fate of breast cancer cells to survive or die. Oncotarget 8, 85984\u201385996 (2017).","journal-title":"Oncotarget"},{"key":"2910_CR53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.isci.2018.11.005","volume":"9","author":"Y Fernandez-Marrero","year":"2018","unstructured":"Fernandez-Marrero, Y., Bachmann, D., Lauber, E. & Kaufmann, T. Negative regulation of BOK expression by recruitment of TRIM28 to regulatory elements in its 3\u2019 untranslated region. iScience 9, 461\u2013474 (2018).","journal-title":"iScience"},{"key":"2910_CR54","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","volume":"30","author":"SM Matulis","year":"2016","unstructured":"Matulis, S. M. et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia 30, 1086\u20131093 (2016).","journal-title":"Leukemia"},{"key":"2910_CR55","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau, P. et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM. Blood 130, 2392\u20132400 (2017).","journal-title":"Blood"},{"key":"2910_CR56","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16078","volume":"8","author":"A Inoue-Yamauchi","year":"2017","unstructured":"Inoue-Yamauchi, A. et al. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat. Commun. 8, 16078 (2017).","journal-title":"Nat. Commun."},{"key":"2910_CR57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","volume":"25","author":"J Montero","year":"2018","unstructured":"Montero, J. & Letai, A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 25, 56\u201364 (2018).","journal-title":"Cell Death Differ."},{"key":"2910_CR58","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-2150-8","volume":"10","author":"RJ Carter","year":"2019","unstructured":"Carter, R. J. et al. Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck. Cell Death Dis. 10, 912 (2019).","journal-title":"Cell Death Dis."},{"key":"2910_CR59","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng, J. et al. Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31, 2075\u20132084 (2017).","journal-title":"Leukemia"},{"key":"2910_CR60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.neo.2017.02.008","volume":"19","author":"EY Kim","year":"2017","unstructured":"Kim, E. Y., Jung, J. Y., Kim, A., Chang, Y. S. & Kim, S. K. ABT-737 synergizes with cisplatin bypassing aberration of apoptotic pathway in non-small cell lung cancer. Neoplasia 19, 354\u2013363 (2017).","journal-title":"Neoplasia"},{"key":"2910_CR61","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","volume":"103","author":"J Kuroda","year":"2006","unstructured":"Kuroda, J. et al. Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl Acad. Sci. USA 103, 14907\u201314912 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2910_CR62","doi-asserted-by":"crossref","first-page":"45088","DOI":"10.18632\/oncotarget.15125","volume":"8","author":"EG Panayotopoulou","year":"2017","unstructured":"Panayotopoulou, E. G. et al. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells. Oncotarget 8, 45088\u201345104 (2017).","journal-title":"Oncotarget"},{"key":"2910_CR63","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1158\/0008-5472.CAN-04-1082","volume":"64","author":"F Essmann","year":"2004","unstructured":"Essmann, F., Engels, I. H., Totzke, G., Schulze-Osthoff, K. & Janicke, R. U. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res. 64, 7065\u20137072 (2004).","journal-title":"Cancer Res."},{"key":"2910_CR64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02910-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:18:10Z","timestamp":1670253490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02910-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":64,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["2910"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-02910-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"27 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"701"}}